glp-1 and fatty liver disease Multiple target tissue effects of analogues on non-alcoholic (NAFLD) non-alcoholic steatohepatitis (NASH) GLP-1 and fatty liver disease.
Description
doi: 10.1111/dom.12824 [DOI] [PubMed] [Google Scholar] 32
PLoS One 13 , e0196625 (2018)
A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss
ACR , albumin-to-creatinine ratio
GLP-1 receptor activation in the brain's appetite control centers promotes satiety and reduces caloric intake, while GIP receptor engagement supports optimal energy balance
